Chronic Renal Failure Therapeutics Market Worth USD 3.17 Billion, at 5% CAGR during 2019-2023 | Technavio

LONDON–(BUSINESS WIRE)–#Biotechnology–According to Technavio Research Report “Global Chronic Renal
Failure Therapeutics Market by product (antihypertensive therapeutics,
antianemia therapeutics, and others) and geographic regions (North
America, Europe, Asia, and ROW) is witnessed to grow USD 3.17
billion, at a CAGR of 5% from 2019 to 2023.”

Free sample report contains market size and forecast, drivers,
challenges, trends, and more – Request for Free Sample @ https://www.technavio.com/talk-to-us?report=Global+Chronic+Renal+Failure+Therapeutics+Market+2019-2023&type=sample&src=report

Global chronic renal failure therapeutics
market: Development of novel hypoxia-inducible factor prolyl hydroxylase
(HIF-PH) inhibitors

ESAs have been the standard of treatment for anemia in patients with
chronic renal failure. However, ESAs involve safety concerns that
include an increased occurrence of vascular access thrombosis,
cardiovascular events, and tumors. Due to such risks, patients receiving
ESAs are often co-administered with various other agents, including
anticoagulants and antihypertensive. Intravenous iron is needed
alongside ESAs, due to their propensity to decrease iron levels during
the correction of hemoglobin, causing functional iron deficiency.

Oral HIF-PH inhibitors such as roxadustat and vadadustat are expected to
help avoid the inconvenience of these co-administered drugs. HIF-PH
agents work by stabilizing the HIF complex and stimulating endogenous
erythropoietin production. Therefore, the development of HIF-PH
inhibitors will fuel the chronic renal failure therapeutics market
growth during the forecast period.

“Apart from the development of novel hypoxia-inducible factor prolyl
hydroxylase (HIF-PH) inhibitors, other factors such as explorative
research toward precision medicine, and strong pipeline and recent
approvals will have a significant impact on the growth of the chronic
renal failure therapeutics market size during the forecast period,” says
a senior analyst at Technavio.

Speak to Research Expert @ https://www.technavio.com/talk-to-us?report=Global+Chronic+Renal+Failure+Therapeutics+Market+2019-2023&type=customization

Global chronic renal failure therapeutics
market: Segmentation analysis

This market research report segments the global chronic renal failure
therapeutics market by product (antihypertensive therapeutics,
antianemia therapeutics, and others), and geographic regions (North
America, Europe, Asia, and ROW).

The North American region led the chronic renal failure therapeutics
market in 2018, followed by Europe, Asia, and ROW respectively. The
growth of the chronic renal failure therapeutics market in North America
can be attributed to factors such as the growing prevalence of chronic
renal failure, rise in geriatric population, the availability of
reimbursement schemes, and new drug approvals.

Global chronic renal failure therapeutics
market: Rising prevalence of chronic renal failure

Some of the major risk factors involved in the development of chronic
renal failure are diabetes, heart disease, high blood pressure, a family
history of kidney failure, and obesity. Furthermore, the prevalence of
chronic renal failure is significantly increasing due to the growing
prevalence of risk factors such as cardiovascular and metabolic
disorders. Also, the disease is known to be prevalent mostly in the
geriatric population. Therefore, the rise in geriatric population and
growing prevalence of risk factors of chronic renal failure will drive
market growth over the next five years. In addition, the development of
novel hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors
will have a positive impact on the market and contribute to its growth
significantly over the forecast period.

Few Major Vendors in the Chronic Renal Failure Therapeutics Market are:

• Amgen Inc.
• AstraZeneca Plc
• Bayer AG
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.

Browse Industries Reports @ Pharmaceuticals,
Biotechnology & Life Sciences

About Technavio

Technavio
is a leading global technology research and advisory company.
Their research and analysis focuses on emerging market trends and
provides actionable insights to help businesses identify market
opportunities and develop effective strategies to optimize their market
positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at [email protected].

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com